Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab plus cetuximab and platinum-based therapy in first-line recurrent or metastatic head and neck squamous cell carcinoma
2015-002222-40Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Patritumab + cetuximab + platinum-based therapy with Placebo + cetuximab + platinum-based therapy (2 arms). Primary endpoint: Progression-free survival. Started Jul 2015; status: completed.
02
Drugs
patritumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2015-002222-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002222-40.